Disease-modifying drugs (DMARDs), Psoriatic arthritis, Real-world evidence

被引：1
|
作者：
Song, J. [1 ,2 ]
Abe, C. [1 ,2 ]
Banefelt, J. [3 ]
Rieem-Dun, A. [3 ]
Willems, D. [1 ]
Morup, M. [1 ]
Taieb, V. [1 ]
Lindberg, I. [1 ]
Welby, S. [1 ]
机构：
[1] UCB Pharma, Braine Lalleud, Belgium
[2] Karolinska Inst, Stockholm, Sweden
[3] Quantify Res, Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Disease-modifying drugs (DMARDs); Psoriatic arthritis; Real-world evidence;
D O I：
10.1136/annrheumdis-2023-eular.3573
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1785 / 1786
页数：2
相关论文
共 50 条
  • [21] Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
    C. McArthur
    C. Daruwalla
    M. Jayeskara
    J. W. L. Brown
    Journal of Neurology, 2023, 270 : 5127 - 5129
  • [22] Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
    Mcarthur, C.
    Daruwalla, C.
    Jayeskara, M.
    Brown, J. W. L.
    JOURNAL OF NEUROLOGY, 2023, 270 (10) : 5127 - 5129
  • [23] The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
    Denis, Agathe
    Sztejkowski, Cedric
    Arnaud, Laurent
    Becker, Guillaume
    Felten, Renaud
    RMD OPEN, 2023, 9 (03):
  • [24] EBM analysis: Classic DMARDs (disease-modifying antirheumatic drugs) and immunosuppressants in arthritis and uveitis
    Niehues, T.
    Winterhalter, S.
    Zierhut, M.
    Michels, H.
    Becker, M. D.
    Heiligenhaus, A.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2007, 224 (06) : 520 - 525
  • [25] TREATMENT PATTERNS IN PSORIATIC ARTHRITIS (PSA) PATIENTS NEWLY INITIATED ON ORAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)
    Zhang, F.
    Guerin, A.
    Gauthier, G.
    Curtis, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 108 - 108
  • [26] Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
    Grijalva, Carlos G.
    Chung, Cecilia P.
    Arbogast, Patrick G.
    Stein, Charles M.
    Mitchel, Edward F., Jr.
    Griffin, Marie R.
    MEDICAL CARE, 2007, 45 (10) : S66 - S76
  • [27] Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data
    Takabayashi, Katsuhiko
    Ando, Fumihiko
    Suzuki, Takahiro
    MODERN RHEUMATOLOGY, 2019, 29 (01) : 87 - 97
  • [28] Switching of Biologic Disease-Modifying Antirheumatic Drugs During the First Year in Patients with Rheumatoid Arthritis in a Real-World Setting
    Meissner, Brian
    Trivedi, Digisha
    You, Min
    Hebden, Tony
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S857 - S857
  • [29] Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis
    Jin, Yinzhu
    Liu, Jun
    Desai, Rishi
    Kim, Seoyoung
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1428 - 1429
  • [30] Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (rheumatoid arthritis disease-modifying anti-rheumatic drug intervention and utilization study) study
    Gibofsky, A
    Palmer, WR
    Goldman, JA
    Lautzenheiser, RL
    Markenson, JA
    Weaver, A
    Schiff, MH
    Keystone, EC
    Paulus, HE
    Harrison, MJ
    Whitmore, JB
    Leff, JA
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (01) : 169 - 183
12345